fbpx

Year

2019
Lund, Sweden, 15:00 CET, 18 December 2019 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, announces changes in its leadership team. Kristina Ingvar starts with the company February 1, 2020 and will formally take on the position as the Executive Vice President Quality Management & Regulatory Affairs of the company...
The aim of a collaboration between researchers in Denmark and the USA is to glean new knowledge about the many different types of neurons that make the human brain work. It could have implications for the design of drugs for conditions such as dementia and for rehabilitation of patients after a stroke. The project is...
An overwhelming total of 293 applications poured in when the Lundbeck Foundation launched a new research funding programme – LF Experiments – earlier this year. The applications have now been reviewed and 31 projects ended up receiving funding. Each project receives almost DKK 2 million on average, and the total allocation to LF Experiments amounted...
The Lundbeck Foundation is awarding grants worth DKK 232 million to six leading neuroscientists: three at Aarhus University and three at the University of Copenhagen. The LF Professorships programme is the Foundation’s largest grant allocation to date. We need to move the brain higher up the agenda. This is why the Lundbeck Foundation is awarding...
Lund, Sweden, 08:45 CET, December 9 2019 BONESUPPORTTM, an emerging leader in orthobiologics for the management of bone injuries, today announced the publication of the Level I clinical study CERTiFy in the highly ranked Journal of Bone and Joint Surgery. The authors concluded that CERAMENT® BVF was as good as autograft with regard to both...
November 25, 2019 at 8:49 AM CET Veloxis to Host Conference Call Following Asahi Kasei Group’s Announcement of a Recommended Conditional Voluntary Public Offer for Veloxis As announced in Company Release no. 18/2019, Veloxis Pharmaceuticals A/S (OMX: VELO) (”Veloxis” or the ”Company”) and Asahi Kasei Pharma Denmark A/S (”Asahi Kasei Pharma Denmark A/S” or the...
November 25, 2019 at 8:29 AM CET Asahi Kasei Group Announces a Recommended Conditional Voluntary Public Offer for Veloxis Veloxis Pharmaceuticals A/S (OMX: VELO) (”Veloxis” or the ”Company”) and Asahi Kasei Pharma Denmark A/S (”Asahi Kasei Pharma Denmark A/S” or the ”Offeror”) have today entered into a transaction agreement (the ”Transaction Agreement”) pursuant to which...
A research project funded by the Lundbeck Foundation will analyse the health data of 2.8 million Danish mothers. The aim is to develop a kind of ‘red flag’ that will detect the onset of postpartum depression. Around 10-15% of all new mothers experience postpartum depression. It is extremely stressful for both mother and baby, partly...
Lund, Sweden, 16:00 CET, November 12 2019 – BONESUPPORT™ an emerging leader in orthobiologics for the management of bone injuries, announces changes in its leadership team that will take place November 18, 2019. Fergus MacLeod starts in the position as the company´s General Manager & Executive Vice President Commercial Operations EUROW. Fergus MacLeod has more...
SNF472 significantly reduced progression of cardiovascular calcification in patients with end stage kidney disease (ESKD) receiving hemodialysis SNF472 treated patients had coronary artery calcium (CAC) volume score progression of 11% from baseline versus 20% in patients receiving placebo (P=0.016) SNF472 was well tolerated Results are remarkable as they have been achieved in patients who continued to...
1 2 3 13

Nyheder

Research project to investigate potential link between headache pills and early-stage spontaneous abortion
6. January 2020
Cancer patients donate living brain cells to scientists
17. December 2019
The Lundbeck Foundation grants 60 million Danish kroner to bold scientific ideas
11. December 2019

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge